Aclarion Announces Agreement with Weill Cornell Medicine
Rhea-AI Summary
Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.
The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.
Positive
- None.
Negative
- None.
News Market Reaction – ACON
On the day this news was published, ACON gained 0.28%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.9% during that session. Argus tracked a trough of -13.1% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $25K to the company's valuation, bringing the market cap to $8.95M at that time. Trading volume was exceptionally heavy at 6.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACON is up 4.4% while peers show mixed moves: BFRG up 15.15%, VSEE up 0.73%, WORX down 8.87%, and DRIO down 17.06%, indicating a stock-specific reaction rather than a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Clinical adoption update | Positive | +4.4% | New physician video and nearly 100 Nociscans at The London Clinic. |
| Mar 24 | Governance challenge | Negative | +10.6% | Investor calls for resignation of board member David Neal. |
| Mar 19 | Rights plan adoption | Neutral | -1.8% | Adoption of one-year limited duration stockholder rights plan. |
| Mar 19 | Shareholder letter | Positive | -1.8% | CEO outlines 2026 catalysts and cash runway into 2028. |
| Mar 17 | Conference participation | Neutral | +0.6% | ROTH Conference meetings highlighting Nociscan progress and balance sheet. |
Recent positive Nociscan-related news has often coincided with upward price moves, while governance and strategic updates have shown mixed alignment with sentiment.
Over the last month, Aclarion has highlighted commercial and strategic progress around its Nociscan platform. On Mar 17 and Mar 19, the company emphasized a strong balance sheet, 2026 catalysts, and adoption initiatives, alongside a limited-duration stockholder rights plan. A shareholder letter on Mar 19 detailed priorities including the CLARITY trial and a cash runway into 2028. On Apr 7, Aclarion showcased nearly 100 Nociscans at The London Clinic with reported up to 97% surgical success when all Nociscan-positive discs are treated. Today’s Weill Cornell agreement continues this commercialization and evidence-building trajectory.
Market Pulse Summary
This announcement highlights expansion of Aclarion’s Nociscan platform into a prospective trial at Weill Cornell Medicine, focused on bone marrow aspirate stem cell concentrate for osteoarthritis and degenerative disc disease. It reinforces the company’s strategy of embedding Nociscan within multidisciplinary spine research and care. In context of prior updates on adoption, balance sheet strength, and 2026 catalysts, investors may watch how many patients receive Nociscan, resulting clinical outcomes, and subsequent reimbursement or commercialization milestones. The global burden of cLBP at 266 million underscores the addressable opportunity.
Key Terms
bone marrow aspirate stem cell concentrate medical
bmac medical
degenerative disc disease medical
irb regulatory
biomarkers medical
saas technical
AI-generated analysis. Not financial advice.
Expands use of Nociscan in groundbreaking trial
BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine.
The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputation for innovation and excellence. The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915.
The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate (BMAC) used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients, selected per Dr. Singh’s clinical evaluation, will also be eligible for Nociscan.
“Our team takes a comprehensive approach to the treatment of spinal disorders. Our multidisciplinary approach to treat pain includes physical therapy and various interventional techniques,” said Jaspal Ricky Singh, MD, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and Rehabilitation Medicine Specialist at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. “Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. 1 Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan can provide critical insights into the location of a patient’s low back pain and improves pain and function when all Nociscan-positive discs are treated.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
References:
- Ravindra VM, Global Spine Journal (2018) 8(8): 784-794, AO Spine.
